Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.

July 17, 2026

Vol.52 No.28

By Paul Goldberg and Claire Marie Porter

Clinical Roundup

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard of care, despite limited evidence to guide the optimal duration of treatment.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer, phase II study finds

AZUR-1 trial, a single arm trial of Jemperli (dostarlimab) in patients with stage 2/3 mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer, met its primary objective, showing a meaningful and sustained clinical complete response rate at 12 months.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Ris-Rez improves overall survival in SCLC, phase III trial finds

ARTEMIS-008, a phase III trial evaluating Ris-Rez (risvutatug rezetecan) in patients with advanced or relapsed small-cell lung cancer, met its primary endpoint of overall survival.

July 17, 2026

Vol.52 No.28

Clinical Trials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research.

July 10, 2026

Vol.52 No.27

By Enrique Velazquez-Villarreal

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.

July 10, 2026

Vol.52 No.27

By Journal of Clinical Oncology

Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer, phase II study finds

Ris-Rez improves overall survival in SCLC, phase III trial finds

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

The long life of a clinical trial
How JCO sustains landmark oncology research

Renew today!

Subscriber content

Never miss an issue!

Login

Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the wayKnudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer, phase II study finds

Ris-Rez improves overall survival in SCLC, phase III trial finds

The challenge of making the move from conversational AI to autonomous scientific discoveryAdvancing from level II to level III AI agents in precision medicine

The long life of a clinical trialHow JCO sustains landmark oncology research

Never miss an issue!

Login

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

The long life of a clinical trial
How JCO sustains landmark oncology research